Novo VP Weighs In on Approval of Lilly’s Obesity Pill

Jamey Millar, executive vice president, US operations of Novo Nordisk, reacts to Eli Lilly’s once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close." (Source: Bloomberg)...

Redirecting to full article...